<VariationArchive VariationID="664988" VariationName="NM_004484.4(GPC3):c.513dup (p.Asp172Ter)" VariationType="Duplication" Accession="VCV000664988" Version="5" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2019-08-14" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="649698" VariationID="664988">
      <GeneList>
        <Gene Symbol="GPC3" FullName="glypican 3" GeneID="2719" HGNC_ID="HGNC:4451" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq26.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="133535745" stop="133985594" display_start="133535745" display_stop="133985594" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="132669772" stop="133119672" display_start="132669772" display_stop="133119672" Strand="-" />
          </Location>
          <OMIM>300037</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GPC3">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GPC3">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_004484.4(GPC3):c.513dup (p.Asp172Ter)</Name>
      <CanonicalSPDI>NC_000023.11:133754000:AAA:AAAA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>Xq26.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="133754000" stop="133754001" display_start="133754000" display_stop="133754001" variantLength="1" positionVCF="133754000" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="132888027" stop="132888028" display_start="132888027" display_stop="132888028" variantLength="1" positionVCF="132888027" referenceAlleleVCF="C" alternateAlleleVCF="CA" />
      </Location>
      <ProteinChange>D118*</ProteinChange>
      <ProteinChange>D172*</ProteinChange>
      <ProteinChange>D156*</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.132888030dup" Assembly="GRCh37">
            <Expression>NC_000023.10:g.132888030dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.133754003dup" Assembly="GRCh38">
            <Expression>NC_000023.11:g.133754003dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009286.1" sequenceAccession="NG_009286" sequenceVersion="1" change="g.236639dup">
            <Expression>NG_009286.1:g.236639dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001164617.2" sequenceAccession="NM_001164617" sequenceVersion="2" change="c.513dup">
            <Expression>NM_001164617.2:c.513dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001158089.1" sequenceAccession="NP_001158089" sequenceVersion="1" change="p.Asp172Ter">
            <Expression>NP_001158089.1:p.Asp172Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001164618.2" sequenceAccession="NM_001164618" sequenceVersion="2" change="c.465dup">
            <Expression>NM_001164618.2:c.465dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001158090.1" sequenceAccession="NP_001158090" sequenceVersion="1" change="p.Asp156Ter">
            <Expression>NP_001158090.1:p.Asp156Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001164619.2" sequenceAccession="NM_001164619" sequenceVersion="2" change="c.351dup">
            <Expression>NM_001164619.2:c.351dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001158091.1" sequenceAccession="NP_001158091" sequenceVersion="1" change="p.Asp118Ter">
            <Expression>NP_001158091.1:p.Asp118Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004484.4" sequenceAccession="NM_004484" sequenceVersion="4" change="c.513dup" MANESelect="true">
            <Expression>NM_004484.4:c.513dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_004475.1" sequenceAccession="NP_004475" sequenceVersion="1" change="p.Asp172Ter">
            <Expression>NP_004475.1:p.Asp172Ter</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001587" Type="nonsense" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_505" sequenceAccession="LRG_505">
            <Expression>LRG_505:g.236639dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_004484.3" sequenceAccession="NM_004484" sequenceVersion="3" change="c.513dupT">
            <Expression>NM_004484.3:c.513dupT</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1603240717" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_004484.4(GPC3):c.513dup (p.Asp172Ter) AND Wilms tumor 1" Accession="RCV000823186" Version="4">
        <ClassifiedConditionList TraitSetID="904">
          <ClassifiedCondition DB="MedGen" ID="CN033288">Wilms tumor 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-11-16" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-11-16" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2019-08-14" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">10402475</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">12713262</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17603795</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="904" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4506" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Wilms tumor 1</ElementValue>
                <XRef ID="MONDO:0008679" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Wilms tumor, somatic</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">WT1</ElementValue>
                <XRef Type="MIM" ID="194070" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15124" />
                <XRef ID="15124" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">PAX6-related aniridia occurs either as an isolated ocular abnormality or as part of the Wilms tumor-aniridia-genital anomalies-retardation (WAGR) syndrome. Aniridia is a pan ocular disorder affecting the cornea, iris, intraocular pressure (resulting in glaucoma), lens (cataract and lens subluxation), fovea (foveal hypoplasia), and optic nerve (optic nerve coloboma and hypoplasia). Individuals with aniridia characteristically show nystagmus and impaired visual acuity (usually 20/100 - 20/200); however, milder forms of aniridia with subtle iris architecture changes, good vision, and normal foveal structure do occur. Other ocular involvement may include strabismus and occasionally microphthalmia. Although the severity of aniridia can vary between and within families, little variability is usually observed in the two eyes of an affected individual. WAGR syndrome. The risk for Wilms tumor is 42.5%-77%; of those who develop Wilms tumor, 90% do so by age four years and 98% by age seven years. Genital anomalies in males can include cryptorchidism and hypospadias (sometimes resulting in ambiguous genitalia), urethral strictures, ureteric abnormalities, and gonadoblastoma. While females typically have normal external genitalia, they may have uterine abnormalities and streak ovaries. Intellectual disability (defined as IQ &lt;74) is observed in 70%; behavioral abnormalities include attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, anxiety, depression, and obsessive-compulsive disorder. Other individuals with WAGR syndrome can have normal intellect without behavioral problems.</Attribute>
                <XRef ID="NBK1360" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301471</ID>
                <ID Source="BookShelf">NBK1294</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301534</ID>
                <ID Source="BookShelf">NBK1360</ID>
              </Citation>
              <Citation Type="general" Abbrev="NSGC, 2004">
                <ID Source="PubMed">15604628</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">32352694</ID>
                <ID Source="BookShelf">NBK556455</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="NCCN, 2023">
                <URL>https://www.nccn.org/professionals/physician_gls/pdf/wilms_tumor.pdf</URL>
                <CitationText>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Wilms Tumor (Nephroblastoma), 2023</CitationText>
              </Citation>
              <XRef ID="654" DB="Orphanet" />
              <XRef ID="CN033288" DB="MedGen" />
              <XRef ID="MONDO:0008679" DB="MONDO" />
              <XRef Type="MIM" ID="194070" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1858415" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2019-08-14">
        <ClinVarSubmissionID localKey="5467055|MedGen:CN033288" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000964035" DateUpdated="2024-02-20" DateCreated="2019-08-14" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-11-16">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">10402475</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">12713262</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17603795</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in GPC3 are known to be pathogenic (PMID: 10402475, 12713262, 17603795). This variant has not been reported in the literature in individuals with GPC3-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Asp172*) in the GPC3 gene. It is expected to result in an absent or disrupted protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GPC3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000023.10:g.132888027_132888028insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN033288" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB5371970</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1858415" TraitType="Disease" MappingType="XRef" MappingValue="CN033288" MappingRef="MedGen">
        <MedGen CUI="CN033288" Name="Wilms tumor 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

